Global Cell Therapy Market Report and Forecast 2023-2031
Market Report I 2023-04-27 I 147 Pages I EMR Inc.
Global Cell Therapy Market Report and Forecast 2023-2031
Global Cell Therapy Market Outlook
The global cell therapy market size attained a value of USD 13.8 billion in 2022. The market is likely to grow at a CAGR of 18.10% during the forecast period of 2023-2031 to attain a value of USD 61.2 billion by 2031.
Cell Therapy Market: Introduction
Cell therapy has emerged as a rapidly growing and innovative segment of the global healthcare industry. It encompasses a diverse range of therapeutic approaches, including regenerative medicine, immunotherapy, and gene therapy, aimed at treating various diseases and disorders by harnessing the power of living cells. The global cell therapy market is anticipated to witness significant growth in the coming years, driven by advancements in biotechnology, increasing investment in research and development, and a rising prevalence of chronic diseases and genetic disorders.
Factors like rising incidence of cancer, cardiovascular diseases, and autoimmune disorders drive the demand for innovative and effective treatment options, are fuelling the growth of the cell therapy market. Developments in gene editing technologies, such as CRISPR/Cas9, have opened new possibilities for cell therapies, offering improved efficacy and safety profiles. Governmental and private investments in cell therapy research have led to a robust pipeline of experimental treatments, which are expected to enter the market in the coming years.
Cell Therapy Market Segmentations
The market can be categorised into cell type, therapy type, therapeutic area, end user, and region.
Market by Cell Type
- Stem Cell
o Bone Marrow
o Blood
o Umbilical Cord
o Adipose Derived Stem Cell
o Others (Placenta, and Non-Specific Cells)
- Non-Stem Cell
Global Cell Therapy Market by Therapy Type
- Autologous
- Allogeneic
Market Breakup by Therapeutic Area
- Musculoskeletal
- Cardiovascular
- Gastrointestinal
- Neurological
- Oncology
- Dermatology
- Wounds and Injuries
- Ocular
- Others
Market Breakup by End User
- Hospitals and Clinics
- Regenerative Medicine Centres
- Diagnostic and Research Centres
- Others
Market Breakup by Region
- North America
- United States of America
- Canada
- Europe
- United Kingdom
- Germany
- France
- Italy
- Others
- Asia Pacific
- China
- Japan
- India
- ASEAN
- Australia
- Others
- Latin America
- Brazil
- Argentina
- Mexico
- Others
- Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Nigeria
- South Africa
- Others
Cell Therapy Market Scenario
The cell therapy market is experiencing significant growth, driven by the increasing prevalence of chronic diseases, genetic disorders, and advancements in biotechnology. This burgeoning industry is marked by a highly competitive landscape, with major pharmaceutical and biotechnology companies, as well as smaller players and start-ups, vying for market share. Factors such as substantial investments in research and development, a strong pipeline of investigational therapies, and an expanding awareness of cell therapies' potential contribute to the market's expansion. However, challenges remain in the form of high treatment costs, ethical concerns, and regulatory hurdles. Nevertheless, the cell therapy market holds immense promise for revolutionizing the treatment landscape across various diseases and conditions.
Key Players in the Global Cell Therapy Market
The report gives an in-depth analysis of the key players involved in the cell therapy market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
- Vericel Corporation
- Kolon TissueGene Inc.
- JCR Pharmaceuticals Co. Ltd.
- MEDIPOST
- Osiris
- Stemedica Cell Technologies Inc.
- NuVasive Inc.
- Fibrocell Science Inc.
- Cellectis
- Praxis Pharmaceutical
- Genzyme Corporation
- Advanced Tissue
- Cells for Cells
- PHARMICELL Co. Ltd
- ANTEROGEN.CO.LTD.
- Novartis AG,
- GlaxoSmithKline plc,
- CELGENE CORPORATION
- Bone Therapeutics
- Cell Therapies
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Cell Therapy Market Overview
3.1 Global Cell Therapy Market Historical Value (2016-2022)
3.2 Global Cell Therapy Market Forecast Value (2023-2031)
4 Global Cell Therapy Market Landscape
4.1 Global Cell Therapy Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Cell Therapy Product Landscape
4.2.1 Analysis by Cell Type
4.2.2 Analysis by Therapy Antigen
4.2.3 Analysis by End User
5 Global Cell Therapy Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter's Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Cell Therapy Market Segmentation
6.1 Global Cell Therapy Market by Cell Type
6.1.1 Market Overview
6.1.2 Stem Cell
6.1.2.1 Bone Marrow
6.1.2.2 Blood
6.1.2.3 Umbilical Cord
6.1.2.4 Adipose Derived Stem Cell
6.1.2.5 Others (Placenta, and Non-Specific Cells)
6.1.3 Non-Stem Cell
6.2 Global Cell Therapy Market by Therapy Type
6.2.1 Market Overview
6.2.2 Autologous
6.2.3 Allogeneic
6.3 Global Cell Therapy Market by Therapeutic Area
6.3.1 Market Overview
6.3.2 Musculoskeletal disorders
6.3.3 Cardiovascular diseases
6.3.4 Neurological disorders
6.3.5 Oncological disorders
6.3.6 Dermatology
6.3.7 Inflammatory and Autoimmune disorders
6.3.8 Others
6.4 Global Cell Therapy Market by End User
6.4.1 Market Overview
6.4.2 Hospitals and Clinics
6.4.3 Regenerative Medicine Centers
6.4.4 Diagnostic and Research Centers
6.4.5 Others
6.5 Global Cell Therapy Market by Region
6.5.1 Market Overview
6.5.2 North America
6.5.3 Europe
6.5.4 Asia Pacific
6.5.5 Latin America
6.5.6 Middle East and Africa
7 North America Cell Therapy Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe Cell Therapy Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific Cell Therapy Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.5 ASEAN
9.6 Australia
9.7 Others
10 Latin America Cell Therapy Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa Cell Therapy Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization
14 Clinical Trials Analysis
14.1 Analysis by Trial Registration Year
14.2 Analysis by Trial Status
14.3 Analysis by Trial Phase
14.4 Analysis by Therapeutic Area
14.5 Analysis by Geography
15 Funding Analysis
15.1 Analysis by Funding Instances
15.2 Analysis by Type of Funding
15.3 Analysis by Funding Amount
15.4 Analysis by Leading Players
15.5 Analysis by Leading Investors
15.6 Analysis by Geography
16 Partnership and Collaborations Analysis
16.1 Analysis by Partnership Instances
16.2 Analysis by Type of Partnership
16.3 Analysis by Leading Players
16.4 Analysis by Geography
17 Regulatory Framework
17.1 Regulatory Overview
17.1.1 US FDA
17.1.2 EU EMA
17.1.3 INDIA CDSCO
17.1.4 JAPAN PMDA
17.1.5 Others
18 Supplier Landscape
18.1 Vericel Corporation
18.1.1 Financial Analysis
18.1.2 Product Portfolio
18.1.3 Demographic Reach and Achievements
18.1.4 Mergers and Acquisitions
18.1.5 Certifications
18.2 Kolon TissueGene Inc.
18.2.1 Financial Analysis
18.2.2 Product Portfolio
18.2.3 Demographic Reach and Achievements
18.2.4 Mergers and Acquisitions
18.2.5 Certifications
18.3 JCR Pharmaceuticals Co. Ltd.
18.3.1 Financial Analysis
18.3.2 Product Portfolio
18.3.3 Demographic Reach and Achievements
18.3.4 Mergers and Acquisitions
18.3.5 Certifications
18.4 MEDIPOST Co. Ltd.
18.4.1 Financial Analysis
18.4.2 Product Portfolio
18.4.3 Demographic Reach and Achievements
18.4.4 Mergers and Acquisitions
18.4.5 Certifications
18.5 Osiris
18.5.1 Financial Analysis
18.5.2 Product Portfolio
18.5.3 Demographic Reach and Achievements
18.5.4 Mergers and Acquisitions
18.5.5 Certifications
18.6 Stemedica Cell Technologies Inc.
18.6.1 Financial Analysis
18.6.2 Product Portfolio
18.6.3 Demographic Reach and Achievements
18.6.4 Mergers and Acquisitions
18.6.5 Certifications
18.7 NuVasive Inc.
18.7.1 Financial Analysis
18.7.2 Product Portfolio
18.7.3 Demographic Reach and Achievements
18.7.4 Mergers and Acquisitions
18.7.5 Certifications
18.8 Fibrocell Science Inc.
18.8.1 Financial Analysis
18.8.2 Product Portfolio
18.8.3 Demographic Reach and Achievements
18.8.4 Mergers and Acquisitions
18.8.5 Certifications
18.8.6 Cells for Cells
18.8.7 Financial Analysis
18.8.8 Product Portfolio
18.8.9 Demographic Reach and Achievements
18.8.10 Mergers and Acquisitions
18.8.11 Certifications
18.9 PHARMICELL Co. Ltd
18.9.1 Financial Analysis
18.9.2 Product Portfolio
18.9.3 Demographic Reach and Achievements
18.9.4 Mergers and Acquisitions
18.9.5 Certifications
18.10 ANTEROGEN.CO.LTD.
18.10.1 Financial Analysis
18.10.2 Product Portfolio
18.10.3 Demographic Reach and Achievements
18.10.4 Mergers and Acquisitions
18.10.5 Certifications
18.11 Novartis AG,
18.11.1 Financial Analysis
18.11.2 Product Portfolio
18.11.3 Demographic Reach and Achievements
18.11.4 Mergers and Acquisitions
18.11.5 Certifications
18.12 CELGENE CORPO RATION
18.12.1 Financial Analysis
18.12.2 Product Portfolio
18.12.3 Demographic Reach and Achievements
18.12.4 Mergers and Acquisitions
18.12.5 Certifications
18.13 Allogene Therapeutics Inc.
18.13.1 Financial Analysis
18.13.2 Product Portfolio
18.13.3 Demographic Reach and Achievements
18.13.4 Mergers and Acquisitions
18.13.5 Certifications
18.14 Stempeutics Research Pvt. Ltd
18.14.1 Financial Analysis
18.14.2 Product Portfolio
18.14.3 Demographic Reach and Achievements
18.14.4 Mergers and Acquisitions
18.14.5 Certifications
19 Global Cell Therapy Market - Distribution Model (Additional Insight)
19.1 Overview
19.2 Potential Distributors
19.3 Key Parameters for Distribution Partner Assessment
20 Key Opinion Leaders (KOL) Insights (Additional Insight)
21 Company Competitiveness Analysis (Additional Insight)
21.1 Very Small Companies
21.2 Small Companies
21.3 Mid-Sized Companies
21.4 Large Companies
21.5 Very Large Companies
22 Payment Methods (Additional Insight)
22.1 Government Funded
22.2 Private Insurance
22.3 Out-of-Pocket
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.